Related Experiment Video
Updated: Jul 12, 2025
Determination of Chemical Inhibitor Efficiency against Intracellular Toxoplasma Gondii Growth Using a Luciferase-Based Growth Assay
Published on: April 29, 2020
An updated review of chemical compounds with anti-Toxoplasma gondii activity
Juan B Rodriguez1, Sergio H Szajnman1
1Departamento de Química Orgánica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Ciudad Universitaria, Pabellón 2, C1428EHA, Buenos Aires, Argentina; CONICET-Universidad de Buenos Aires, Unidad de Microanálisis y Métodos Físicos en Química Orgánica (UMYMFOR), C1428EHA, Buenos Aires, Argentina.
Abstract:
The opportunistic apicomplexan parasite Toxoplasma gondii is the etiologic agent for toxoplasmosis, which can infect a widespread range of hosts, particularly humans and warm-blooded animals. The present chemotherapy to treat or prevent toxoplasmosis is deficient and is based on diverse drugs such as atovaquone, trimethoprim, spiramycine, which are effective in acute toxoplasmosis. Therefore, a safe chemotherapy is required for toxoplasmosis considering that its responsible agent, T. gondii, provokes severe illness and death in pregnant women and immunodeficient patients. A certain disadvantage of the available treatments is the lack of effectiveness against the tissue cyst of the parasite. A safe chemotherapy to combat toxoplasmosis should be based on the metabolic differences between the parasite and the mammalian host. This article covers different relevant molecular targets to combat this disease including the isoprenoid pathway (farnesyl diphosphate synthase, squalene synthase), dihydrofolate reductase, calcium-dependent protein kinases, histone deacetylase, mitochondrial electron transport chain, etc.
Insights
Current toxoplasmosis treatments are insufficient, especially against parasite tissue cysts. New therapies targeting metabolic differences in Toxoplasma gondii are needed for safer, more effective toxoplasmosis chemotherapy.
Area of Science:
- Medical Parasitology
- Drug Discovery
- Molecular Biology
Background:
- Toxoplasma gondii, an opportunistic apicomplexan parasite, causes toxoplasmosis in humans and animals.
- Current chemotherapy for toxoplasmosis is limited, with drugs like atovaquone and spiramycin effective only in acute stages.
- Existing treatments fail against the parasite's tissue cyst stage and pose risks to pregnant women and immunocompromised individuals.
Purpose of the Study:
- To highlight the need for safe and effective chemotherapy against Toxoplasma gondii.
- To explore novel molecular targets for combating toxoplasmosis.
- To emphasize developing treatments based on metabolic disparities between the parasite and host.
Main Methods:
- Review of molecular targets for anti-toxoplasmosis drug development.
- Analysis of metabolic pathways unique to T. gondii.
- Identification of key enzymes and pathways for therapeutic intervention.
Main Results:
- Identified several promising molecular targets, including the isoprenoid pathway (farnesyl diphosphate synthase, squalene synthase), dihydrofolate reductase, calcium-dependent protein kinases, histone deacetylase, and the mitochondrial electron transport chain.
- Highlighted the potential of targeting parasite-specific metabolic processes for drug development.
- Emphasized the need for therapies effective against all parasite stages, including tissue cysts.
Conclusions:
- Developing novel chemotherapy for toxoplasmosis requires targeting unique parasite metabolic pathways.
- Molecular targets such as those in the isoprenoid pathway and protein kinases offer potential for new drug development.
- Future research should focus on creating safe and effective treatments effective against all stages of T. gondii infection.
Related Concept Videos
01:27Chemical Agents for Microbial Control
01:28Antimicrobial Effectiveness